
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc recorded an improvement in gross margin year-over-year, primarily driven by a higher mix of consumables revenue, indicating a strong demand for its products. The company highlighted that the utilization of its Revio platform reached its peak since launch, suggesting robust engagement and increased sales within the Americas region. Additionally, management expressed optimism regarding sequential growth in Vega placements, which may contribute positively to the company's revenue and profitability throughout the year.
Bears say
Pacific Biosciences of California Inc. faces a negative outlook primarily due to a projected decline in gross margins, expected to fall below the 40.4% reported in the previous quarter. There are concerns regarding stagnant utilization and weaker-than-anticipated demand for new instruments, which could jeopardize the company's financial targets for 2026. Additionally, persistent demand weakness in China, noted by life science tools companies throughout FY23, indicates ongoing challenges that could impact revenue growth into 2024.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares